US OptionsDetailed Quotes
IRWD250117P5000
- 0.70
- -0.05-6.67%
15min DelayClose Dec 24 13:00 ET
0.70High0.70Low
0.70Open0.75Pre Close10 Volume102 Open Interest5.00Strike Price700.00Turnover100.53%IV6.72%PremiumJan 17, 2025Expiry Date0.39Intrinsic Value100Multiplier23DDays to Expiry0.31Extrinsic Value100Contract SizeAmericanOptions Type-0.5716Delta0.3339Gamma6.59Leverage Ratio-0.0095Theta-0.0019Rho-3.76Eff Leverage0.0046Vega
Ironwood Pharmaceuticals Stock Discussion
Sign in to post a comment
$United Therapeutics (UTHR.US)$ Phase 3
$Ironwood Pharmaceuticals (IRWD.US)$ Phase 3
$Liquidia (LQDA.US)$ Phase 3
$United Therapeutics (UTHR.US)$ Phase 3
$MorphoSys (MOR.US)$ Phase 3
$Immunocore (IMCR.US)$ Phase 3
$Crinetics (CRNX.US)$ Phase 3
$UroGen Pharma Ltd (URGN.US)$ Phase 3
$AstraZeneca (AZN.US)$ Phase 3
$AstraZeneca (AZN.US)$ Phase 3
$AstraZeneca (AZN.US)$ Phase 3
$AstraZeneca (AZN.US)$ Phase 3
$Capricor Therapeutics (CAPR.US)$ Phase 3
$Annexon (ANNX.US)$ Phase 3
$Lipocine (LPCN.US)$ Phase 3 ...
$Ironwood Pharmaceuticals (IRWD.US)$ Phase 3
$Liquidia (LQDA.US)$ Phase 3
$United Therapeutics (UTHR.US)$ Phase 3
$MorphoSys (MOR.US)$ Phase 3
$Immunocore (IMCR.US)$ Phase 3
$Crinetics (CRNX.US)$ Phase 3
$UroGen Pharma Ltd (URGN.US)$ Phase 3
$AstraZeneca (AZN.US)$ Phase 3
$AstraZeneca (AZN.US)$ Phase 3
$AstraZeneca (AZN.US)$ Phase 3
$AstraZeneca (AZN.US)$ Phase 3
$Capricor Therapeutics (CAPR.US)$ Phase 3
$Annexon (ANNX.US)$ Phase 3
$Lipocine (LPCN.US)$ Phase 3 ...
17
2
2
$Ironwood Pharmaceuticals (IRWD.US)$ shares sank almost 40% after the drugmaker said its global phase III trial of Apraglutide, a treatment for short bowel syndrome, missed two of its four secondary goals.
That muddies the prospects for the company that's seeking to expand its product pipeline beyond Linzess.
Ironwood, which has been operating at a loss, sourced almost ll of its $117.6 million revenue in 2023 from its collaborati...
That muddies the prospects for the company that's seeking to expand its product pipeline beyond Linzess.
Ironwood, which has been operating at a loss, sourced almost ll of its $117.6 million revenue in 2023 from its collaborati...
7
🎯 Ph 3 readouts in Q1 2024...
$Pfizer (PFE.US)$ Phase 3
$Palatin Technologies (PTN.US)$ Phase 3
$Annovis Bio (ANVS.US)$ Phase 3
$BioCardia (BCDA.US)$ Phase 3
$Atea Pharmaceuticals (AVIR.US)$ Phase 3
$Ironwood Pharmaceuticals (IRWD.US)$ Phase 3
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 3
$Axsome Therapeutics (AXSM.US)$ Phase 3
$ $Novocure (NVCR.US)$ Phase 3
$ROCHE HOLDING AG (RHHBY.US)$ Phase 3
$FibroGen (FGEN.US)$ Phase 3
$ACADIA Pharmaceuticals (ACAD.US)$ Phase 3
$Sellas Life Sciences (SLS.US)$...
$Pfizer (PFE.US)$ Phase 3
$Palatin Technologies (PTN.US)$ Phase 3
$Annovis Bio (ANVS.US)$ Phase 3
$BioCardia (BCDA.US)$ Phase 3
$Atea Pharmaceuticals (AVIR.US)$ Phase 3
$Ironwood Pharmaceuticals (IRWD.US)$ Phase 3
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 3
$Axsome Therapeutics (AXSM.US)$ Phase 3
$ $Novocure (NVCR.US)$ Phase 3
$ROCHE HOLDING AG (RHHBY.US)$ Phase 3
$FibroGen (FGEN.US)$ Phase 3
$ACADIA Pharmaceuticals (ACAD.US)$ Phase 3
$Sellas Life Sciences (SLS.US)$...
16
Thomas McCourt's recent sale at the current share price of US$14.58 raises caution. More selling than buying by insiders over the past year and low insider ownership could concern potential investors.
$Pfizer (PFE.US)$ Phase 3
$Regenxbio (RGNX.US)$ Phase 3
$Annovis Bio (ANVS.US)$ Phase 3
$Atea Pharmaceuticals (AVIR.US)$ Phase 3
$Ironwood Pharmaceuticals (IRWD.US)$ Phase 3
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 3
$Vertex Pharmaceuticals (VRTX.US)$ Phase 3
$KalVista Pharmaceuticals (KALV.US)$ Phase 3
$Axsome Therapeutics (AXSM.US)$ Phase 3
$Novocure (NVCR.US)$ Phase 3
$ROCHE HOLDING AG (RHHBY.US)$ Phase 3
$FibroGen (FGEN.US)$ Phase 3
$Applied Therapeutics (APLT.US)$ Phase 3
$ACADIA Pharmaceuticals (ACAD.US)$ Phase 3 ...
$Regenxbio (RGNX.US)$ Phase 3
$Annovis Bio (ANVS.US)$ Phase 3
$Atea Pharmaceuticals (AVIR.US)$ Phase 3
$Ironwood Pharmaceuticals (IRWD.US)$ Phase 3
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 3
$Vertex Pharmaceuticals (VRTX.US)$ Phase 3
$KalVista Pharmaceuticals (KALV.US)$ Phase 3
$Axsome Therapeutics (AXSM.US)$ Phase 3
$Novocure (NVCR.US)$ Phase 3
$ROCHE HOLDING AG (RHHBY.US)$ Phase 3
$FibroGen (FGEN.US)$ Phase 3
$Applied Therapeutics (APLT.US)$ Phase 3
$ACADIA Pharmaceuticals (ACAD.US)$ Phase 3 ...
20
1
$Pfizer (PFE.US)$ Phase 2
$Leap Therapeutics (LPTX.US)$ Phase 2
$Vera Therapeutics (VERA.US)$ Phase 2b
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$Akero Therapeutics (AKRO.US)$ Phase 2b
$Spruce Biosciences (SPRB.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Annexon (ANNX.US)$ Phase 2a
$Roivant Sciences (ROIV.US)$...
$Leap Therapeutics (LPTX.US)$ Phase 2
$Vera Therapeutics (VERA.US)$ Phase 2b
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$Akero Therapeutics (AKRO.US)$ Phase 2b
$Spruce Biosciences (SPRB.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Annexon (ANNX.US)$ Phase 2a
$Roivant Sciences (ROIV.US)$...
25
1
$Cellectar BioSciences (CLRB.US)$ Phase 2
$Regenxbio (RGNX.US)$ Phase 2
$Leap Therapeutics (LPTX.US)$ Phase 2
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$EyePoint Pharmaceuticals (EYPT.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Disc Medicine (IRON.US)$ Phase 2
$Atea Pharmaceuticals (AVIR.US)$ Phase 2
$Allakos (ALLK.US)$ Phase 2 ...
$Regenxbio (RGNX.US)$ Phase 2
$Leap Therapeutics (LPTX.US)$ Phase 2
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$EyePoint Pharmaceuticals (EYPT.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Disc Medicine (IRON.US)$ Phase 2
$Atea Pharmaceuticals (AVIR.US)$ Phase 2
$Allakos (ALLK.US)$ Phase 2 ...
38
9
1
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Investor sentiment for Ironwood Pharmaceuticals is negative. Potential disconnect between business fundamentals and market valuation could reveal investment opportunities.
$Ironwood Pharmaceuticals (IRWD.US)$ 25205 West Street Springfield Louisiana 70462 Charles d avants charlesdavants18@mail.com
Hello mooers, welcome to another week of the FDA calendar. Here are what happened last week and what's coming up this week.
Next week big pharma companies such as $Biogen (BIIB.US)$ , $Sage Therapeutics (SAGE.US)$ , and $Ironwood Pharmaceuticals (IRWD.US)$ will release their quarterly earnings report.
BIGGEST MOVERS FROM THIS WEEK
$Hillstream BioPharma (HILS.US)$ shares continued to trade up this week after it announced initial results from a study...
Next week big pharma companies such as $Biogen (BIIB.US)$ , $Sage Therapeutics (SAGE.US)$ , and $Ironwood Pharmaceuticals (IRWD.US)$ will release their quarterly earnings report.
BIGGEST MOVERS FROM THIS WEEK
$Hillstream BioPharma (HILS.US)$ shares continued to trade up this week after it announced initial results from a study...
7
3
9
No comment yet
Jimmy1819 : have you been investing professionally or as a hobby?
Coach Donnie : Awesome @Meltyy